Vistin Pharma ASA

OB:VISTN Stock Report

Market Cap: NOK 1.1b

Vistin Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OB:VISTN Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
26 Sep 24BuyNOK 1,410,000Saga Pure ASACompany50,000NOK 28.20
13 Sep 24BuyNOK 6,282,499Saga Pure ASACompany250,000NOK 25.13
23 Aug 24BuyNOK 6,750,001Saga Pure ASACompany300,000NOK 22.50

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of VISTN?
Owner TypeNumber of SharesOwnership Percentage
Public Companies00%
Private Companies4,963,26411.2%
Institutions9,950,67622.4%
General Public13,796,16631.1%
Individual Insiders15,634,48635.3%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 68.79% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
28.4%
Øyvin Brøymer
12,575,000NOK 308.1m0%no data
9.47%
Holmen Fondsforvaltning Ltd.
4,200,379NOK 102.9m0%5.38%
6.75%
Pactum AS
2,991,773NOK 73.3m0%25.98%
3.88%
MP Pensjon PK
1,719,848NOK 42.1m0%0.53%
1.69%
Storkleiven AS
751,000NOK 18.4m0%no data
1.69%
August Ringvold Agenturer AS
750,315NOK 18.4m0%no data
1.62%
Lucellum AS
720,000NOK 17.6m0%no data
1.59%
Henrik Haavie
706,253NOK 17.3m0%no data
1.22%
Tigerstaden AS
540,170NOK 13.2m0%2.54%
1.22%
Ivar Loges
540,000NOK 13.2m0%no data
1.19%
Surfside Holding AS
527,960NOK 12.9m0%no data
1.17%
Tom Staavi
519,324NOK 12.7m0%no data
1.15%
Cortex As
508,989NOK 12.5m0%no data
1.13%
Sanden Equity AS
500,000NOK 12.2m0%no data
1.12%
DNB Asset Management AS
498,506NOK 12.2m0%no data
0.92%
Delta A/S
410,000NOK 10.0m0%no data
0.9%
Ginko As
400,000NOK 9.8m0%no data
0.89%
Wem Invest AS
395,000NOK 9.7m0%no data
0.73%
Oystein Spetalen
323,650NOK 7.9m0%no data
0.68%
Niels Aall
301,658NOK 7.4m0%no data
0.64%
Nicolai Eger
284,040NOK 7.0m0%no data
0.32%
Kjell-Erik Nordby
140,000NOK 3.4m0%no data
0.17%
Vegard Heggem
77,360NOK 1.9m0%no data
0.17%
Magnus Tolleshaug
75,000NOK 1.8m0%no data
0.11%
Alexander Karlsen
50,000NOK 1.2m0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/19 01:35
End of Day Share Price 2025/06/19 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vistin Pharma ASA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mikkel Nyholt-SmedsengCarnegie Investment Bank AB